Welcome to BioSeeker Group!

Vascular Targeting Agents: Emerging Competitors

Additional Information

Published Date Feb 8, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 69
PDF Fact Sheet View Fact Sheet for the report Vascular Targeting Agents: Emerging Competitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Vascular Targeting Agents: Emerging Competitors.

    To find out more about Vascular Targeting Agents: Emerging Competitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Vascular Targeting Agents: Emerging Competitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

In this issue of Cancer Highlights, BioSeeker Group analyzes the progress made for vascular targeting agents (VTA). You will receive an update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. In only a few years time the number of candidates has been doubled, expanding from a handful of drugs to more than twenty. Several of these have entered clinical evaluation. Earlier and most talked of candidates still remain at the top. However, the list of emerging competitors is growing and at least seven new VTAs have recently entered clinic settings. Not so far away, there are also several vascular targeting agents that are on the brim of initiating Phase I trials.

Vascular targeting agents with the longest clinical experience are the small molecular drugs that mediate their action on the tubulin cytoskeleton. In review of 2004, several companies have announced progression on existing studies. In addition two new Phase II trials and two new Phase I trials have been launched. Several companies have made announcements of plans to initiate new trials during 2005. A few candidates are now in planning for Phase III trial studies.

Despite compelling preclinical data, the conjugated antibodies have been delayed in comparison to the small molecule approaches. Trial initiation is thus long overdue for many. We have devoted an entire section of this Highlight to "Monoclonal antibodies as Delivery Vehicles" where the progression for several of the most important conjugated antibodies is outlined. One of these antibodies is already in Phase I and for which plans are laid for Phase II during 2005.

The close relation between vascular targeting and anti-angiogenesis also make it possible for new competitors to enter the scene in near future. One relative large company, with a strong anti-angiogenesis antibody portfolio, has already announced to hold a vascular targeting antibody in early stage of development.

In total BioSeeker Group has identified 26 different therapies that have been developed utilizing vascular targeting strategies:

3G4, ABT-751, AVE8062A, AZD4440, BCH-19746, BCH-23541, CA4P, DMXAA, E4G10, EndoTAG-1, EndoTAG-2, Exherin, ILX-651, MLN2704, MLN591, MLN591RL, MN-029, MX116407, NPI-2358, OXi4503, OXi6197, OXi8009, Tarvacin, TZT-1027, VEGF121/rGel, ZD6126

Introduction
More Vascular Targeting Drugs in Clinical Trial
Table 1 Summary of VTA agents under development
The Vanguard VTA in New Clinical Programs
Combination of VTAs and antiangiogenic agents
The Non-Combretastatins Agents that Destabilize Microtubules
Antimicrotubule Agents with Vascular Targeting Potential
Monoclonal Antibodies as Delivery Vehicles
Targeting Endothelial Cell-Specific Adhesion
Encapsulation in cationic liposomes

Disclaimer
Liability
Completeness

Appendix

List of Tables

Table 2. CA4P Near Term Progress
Table 3. Oxi 4503 Near Term Progress
Table 4. AVE8062A Near Term Progress
Table 5. ZD6126 Near Term Progress
Table 6. DMXAA Near Term Progress
Table 7. ABT-751 Near Term Progress
Table 8. MN-029 Near Term Progress
Table 9. MX116407 Near Term Progress
Table 10. NPI-2358 Near Term Progress
Table 11. TZT-1027 Near Term Progress
Table 12. ILX-651 Near Term Progress
Table 13. Peregrines VTA and APT platforms Near Term Progress
Table 14. VEGF121/rGelonin Near Term Progress
Table 15. MLN2704 Near Term Progress
Table 16. Adherexs cadherin platform Near Term Progress
Table 17. E4G10 Near Term Progress
Table 18. EndoTAG-1 Near Term Progress

Drugs covered in this report:
3G4, ABT-751
AVE8062A
AZD4440
BCH-19746
BCH-23541
CA4P
DMXAA
E4G10
EndoTAG-1
EndoTAG-2
Exherin
ILX-651
MLN2704
MLN591
MLN591RL
MN-029
MX116407
NPI-2358
OXi4503
OXi6197
OXi8009
Tarvacin
TZT-1027
VEGF121/rGel
ZD6126

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Vascular Targeting Agents: Emerging Competitors.
    To find out more about Vascular Targeting Agents: Emerging Competitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Vascular Targeting Agents: Emerging Competitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More

Other selected research from the 'R&D' category:


New Concepts in Cancer Therapeutics
There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents.... Learn More


Transcriptional Misregulation in Cancer Drug Pipeline Update
BioSeeker Group have identified 292 companies plus partners who are today developing 350 transcriptional misregulation targeting drugs in 1432 developmental projects in cancer across 229 different targets. In addition, there are 6 suspended drugs and another 204 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More

Other selected research from the 'Line of Treatment' category:


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More


Protein Kinase Inhibitors in Oncology Drug Pipeline Update
BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More